{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:12:26Z","timestamp":1791335546809,"version":"4.3.1"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> We evaluated the clinical impact of germ-line BRCA1\/2 mutations in patients with epithelial ovarian cancer (EOC) on responses to first and subsequent lines of chemotherapy, treatment-free interval (TFI) between each line of therapy, and overall survival (OS). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Twenty-two EOC patients with germ-line BRCA1 or BRCA2 mutations (BRCA-positive) were selected from our database and matched (1:2) with 44 nonhereditary EOC controls (defined by no associated personal history of breast cancer and no family history of breast and ovarian cancer or an uninformative BRCA mutation test) for stage, histologic subtype, age, and year of diagnosis. All patients received primary platinum-based chemotherapy. Statistical comparisons included responses after first-, second-, and third-line treatment (\u03c7<jats:sup>2<\/jats:sup>\/Fisher's exact test) and median OS (Kaplan-Meier method\/log-rank test). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Compared with controls, BRCA-positive patients had higher overall (95.5% v 59.1%; P = .002) and complete response rates (81.8% v 43.2%; P = .004) to first line treatment, higher responses to second and third line platinum-based chemotherapy (second line, 91.7% v 40.9% [P = .004]; third line, 100% v 14.3% [P = .005]) and longer TFIs. A significant improvement in median OS in BRCA-positive patients compared with controls was observed from both time of diagnosis (8.4 v 2.9 years; P &lt; .002) and time of first relapse (5 v 1.6 years; P &lt; .001). BRCA status, stage, and length of first response were independent prognostic factors from time of first relapse. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> BRCA-positive EOC patients have better outcomes than nonhereditary EOC patients. There exists a clinical syndrome of BRCAness that includes serous histology, high response rates to first and subsequent lines of platinum-based treatment, longer TFIs between relapses, and improved OS. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.16.1703","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:14:37Z","timestamp":1225152877000},"page":"5530-5536","source":"Crossref","is-referenced-by-count":396,"title":["\u201cBRCAness\u201d Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With <i>BRCA1<\/i> and <i>BRCA2<\/i> Mutations"],"prefix":"10.1200","volume":"26","author":[{"given":"David S.P.","family":"Tan","sequence":"first","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rothermundt","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bancroft","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Eeles","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shanley","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ardern-Jones","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Norman","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B.","family":"Kaye","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gore","sequence":"additional","affiliation":[{"name":"From the Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London; Section of Medicine, Institute for Cancer Research; Department of Medical Statistics, Royal Marsden Hospital; and the Translational Cancer Genetics Team, The Institute of Cancer Research, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1365"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91578-4"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1086\/301749"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-004-9552-0"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20429"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020119"},{"key":"R7","unstructured":"Aida H, Takakuwa K, Nagata H, et al: Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4:235,1998-240,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.463"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611073351901"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2260"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11310"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21276"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6905"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.397"},{"key":"R15","unstructured":"Pharoah PD, Easton DF, Stockton DL, et al: Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer United Kingdom Coordinating Committee for Cancer Res (UKCCCR) Familial Ovarian Cancer Study Group Cancer Res 59:868,1999-871,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.2820710218"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2517"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361713"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Modan B: BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 336:1255,1997,","DOI":"10.1056\/NEJM199704243361713"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02434-6"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb02195.x"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1101\/sqb.2005.70.012"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Yap TA, Boss DS, Fong PC, et al: First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1\/2 mutation carriers. J Clin Oncol 25:145s,2007,  (suppl; abstr 3529)","DOI":"10.1200\/jco.2007.25.18_suppl.3529"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1083"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-006-9112-x"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704173361602"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh081"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600859"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.1.61"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.7.564"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1396"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.16.1703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:19:52Z","timestamp":1653524392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.16.1703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":32,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2008,12,1]]}},"alternative-id":["10.1200\/JCO.2008.16.1703"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.16.1703","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}